Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity.

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Abstract Text:

Objective. Leptin and adiponectin have been implicated in the pathogenesis and progression of non-alcoholic steatohepatitis (NASH) and chronic hepatitis C (CHC), but little is known about the role of resistin in chronic liver diseases. The objective of this study was to investigate serum levels of the above three adipokines in relation to the etiology of liver disease and to determine their associations with histological severity. Material and methods. We prospectively evaluated 146 patients (HBeAg-negative chronic hepatitis B (CHB): 52, CHC: 70, NASH: 24) who consecutively underwent liver biopsy. Detailed epidemiological, anthropometric and laboratory data were recorded. Histological lesions were evaluated blindly according to the Ishak and the Brunt classifications for CHB/CHC and NASH, respectively. Results. Serum adipokine levels were similar between CHB and CHC patients, while CHB/CHC patients had significantly lower leptin levels compared with NASH patients (8.3+/-7.3 versus 17.6+/-16.6 ng/ml, p=0.012) and higher adiponectin (10.2+/-5.1 versus 7.5+/-4 microg/ml, p=0.018) and resistin levels (7.1+/-2.5 versus 5.7+/-2.8 ng/ml, p=0.016). In CHB/CHC, there was no significant association between steatosis or necroinflammation and levels of adipokines, while the presence of moderate/severe fibrosis (stages 4-6) was associated with higher leptin and adiponectin levels in male but not in female patients and with lower resistin levels irrespective of gender or other factors (adjusted odds ratio=0.788, p=0.035). Conclusions. Serum adipokine levels depend on the etiology of liver disease differing between chronic viral hepatitis and NASH, but not between CHB and CHC. In CHB/CHC, resistin levels are independently associated with fibrosis severity, whereas in the association of leptin and adiponectin levels with fibrosis, it seems to be a gender effect.

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Scandinavian journal of gastroenterology

VOLUME: 43

Page Numbers: 1128-36

Journal Abbreviation: Scand. J. Gastroenterol.

ISSN: 1502-7708

DAY: 19

MONTH: 08

YEAR: 2008

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 60105

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity.

AFFILIATION: Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece.

Country: Norway

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Scand J Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity Related Publications

• A 70-year-old stock-breeder with tricuspid valve and defibrillator lead brucella endocarditis.
• Adipokines and insulin resistance in chronic hepatitis C.
• Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation.
• An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features.
• Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
• Campylobacter fetus bacteraemia in a healthy individual: clinical and therapeutical implications.
• Changes of liver and muscle enzymes activity in patients with rigor.
• Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.
• Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.
• Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
• Myelodysplastic syndrome presenting as acquired ichthyosis.
• Performance Characteristics of Microparticle Enzyme and Chemiluminescence Immunoassays for Measurement of Anti-HBc Immunoglobulin M in Sera of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection.
• Pseudohyperkalemia in serum: a new insight into an old phenomenon.
• Sensorineural hearing loss complicating severe rickettsial diseases: report of two cases.
• Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity.
• Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
• Severe rhabdomyolysis with hypoglycemia in an adult patient with carnitine palmitoyltransferase II deficiency.
• Systemic Vasculitis With Gastrointestinal Involvement in an HIV-Infected Adult.
• Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.
• Usefulness of enzyme-linked immunosorbent assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum.
• Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.